抗体
试剂盒
多肽
探针
蛋白
组织芯片
产品中心
Product Center
Research Grade Actoxumab
All
TD-JN085016_1.jpg
- Catalog： TD-JN085016
- Clonality： mAb
- Application： Research Grade Biosimilar
- Synonyms： CDA1,MBL-CDA1,MDX-066,MK-3415A(combinationofactoxumabandbezlotoxumab),CAS:1245634-25-6
-
规格：
1mg
-
价格：
¥询价
定制服务咨询
Research Grade Actoxumab
| Catalog No. | TD-JN085016 |
|---|---|
| Species reactivity | Clostridioides difficile |
| Applications | Research Grade Biosimilar |
| Host species | Human |
| Isotype | IgG1-kappa |
| Expression system | Mammalian Cells |
| Clonality | Monoclonal |
| Target | Toxin A/tcdA |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G, purified from cell culture supernatant. |
| Accession | P16154 |
| Form | Liquid |
| Storage buffer | 0.01M PBS,pH7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | CDA1,MBL-CDA1,MDX-066,MK-3415A(combinationofactoxumabandbezlotoxumab),CAS:1245634-25-6 |
| Background | Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB. |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|
|
SDS-PAGE for Research Grade Actoxumab. |